PRP and PRF Injections for the Under-Eye Area: How Platelet Therapy Rejuvenates Periorbital Skin, and When Fillers or Surgery Are Still the Answer

Platelet-rich plasma and platelet-rich fibrin have moved steadily from wound-healing applications into periorbital aesthetics, and the questions patients bring to consultation have grown more specific. They want to know exactly what is being injected, which type of darkness or hollowing actually responds, and - critically - when the honest answer is that a filler or a surgical procedure will do what platelet therapy cannot. This article covers all three questions in order: how the products are made, what they do at a cellular level, what the published trials show, and where the treatment ladder ends for candidates who need more than biology can deliver.

How a Vial of Blood Becomes a Treatment: The Centrifuge Process for PRP and PRF

Both products begin with a standard blood draw from a peripheral vein. After that, the preparation diverges in ways that produce meaningfully different products - not two versions of the same thing.

Making PRP: The Two-Spin Protocol

Preparing platelet-rich plasma requires adding an anticoagulant to the collection tube before the draw. The anticoagulant prevents clotting during processing, which matters because the protocol calls for two separate high-speed centrifuge spins. The first spin separates red blood cells from the upper plasma layer. That plasma layer transfers to a second tube and spins again at a different speed, concentrating platelets into a small pellet at the bottom. The operator discards most of the platelet-poor plasma above, then resuspends the pellet in the remaining fluid.

The result contains roughly 2 to 5 times the platelet concentration found in whole blood. The anticoagulant keeps platelets inactivated until injection - contact with tissue triggers growth factor release at the treatment site. The liquid consistency allows it to pass easily through fine-gauge needles, which matters around the eye where tissue planes are thin.

Making PRF: The Single Slow Spin

Platelet-rich fibrin is prepared without any anticoagulant. Blood is drawn into plain tubes and centrifuged almost immediately at a lower speed - roughly 700 to 1,000 rpm - for a shorter duration. Without anticoagulant, fibrinogen in the plasma begins converting to fibrin naturally during the spin. The result is a three-layered column: red cells at the bottom, a fibrin clot in the middle (the PRF layer), and platelet-poor plasma at the top.

The fibrin layer is the treatment product. It contains platelets at roughly 10 times the concentration of whole blood - higher than standard PRP. More importantly, it retains leukocytes and circulating stem cells that the PRP double-spin process largely removes. The fibrin matrix acts as a three-dimensional scaffold: rather than releasing growth factors all at once on injection, it parcels them out gradually over 7 to 10 days. That slow-release behavior is the defining biological difference between the two products.

The Growth Factor Cascade: What Happens in the Skin After Injection

Platelets are storage vessels for proteins that direct tissue repair. When activated, they release growth factors that communicate with fibroblasts - the cells responsible for building the structural proteins of skin. Four signals carry most of the biological weight in periorbital rejuvenation:

• Platelet-derived growth factor (PDGF) - drives fibroblast proliferation and migration into the treated zone, increasing the density of collagen-producing cells.
• Transforming growth factor-beta (TGF-β) - directs fibroblasts to synthesize collagen types I and III, the forms responsible for firmness and structural integrity, along with elastin and extracellular matrix proteins.
• Vascular endothelial growth factor (VEGF) - stimulates angiogenesis, the formation of new capillary networks, improving local circulation and oxygenation in the dermis.
• Insulin-like growth factor (IGF) - supports cell survival and amplifies the collagen synthesis signals sent by TGF-β.

VEGF's role deserves separate attention because it connects directly to one of the most common complaints: the bluish or purple tint under the eyes. In vascular-type dark circles, thin periorbital skin allows the underlying venous plexus and orbicularis muscle to show through. New capillary growth improves perfusion and reduces vascular stasis, making the area appear less congested. Over several months, increased collagen synthesis adds dermal thickness and provides an additional optical barrier between the skin surface and the underlying vessels. This mechanism is real - but it addresses only the vascular cause of darkness. It does not affect melanin deposits, shadowing from hollowing, or skin laxity.

PRP vs. PRF: Which Product Fits Which Periorbital Problem

The 2025 systematic review by Sollitto and colleagues in the Journal of Cosmetic Dermatology found PRP showed stronger evidence specifically for pigmented dark circles, while PRF was associated with improvements in skin texture, wrinkles, and crepiness. In most periorbital applications today, PRF has become the preferred product because its sustained release profile and leukocyte content suit the slow remodeling cycle of periorbital skin. For patients whose primary complaint is melanin-driven pigmentation, PRP retains a distinct role.

What the Clinical Evidence Shows: Dark Circles, Fine Lines, Crepey Skin, and Mild Hollowness

The published evidence base is growing but still characterized by small trials and follow-up periods measured in months rather than years. Effect sizes are real but should be framed honestly.

A 2026 randomized split-face trial by Behrangi and colleagues in the Journal of Cosmetic Dermatology found both PRP and PRF significantly improved periorbital hyperpigmentation, fine wrinkles, and mild hollowness compared to untreated control sides of the same face. PRF showed more stable reduction in melanin and erythema indices over the follow-up period. Split-face design is a methodological strength because each patient acts as their own control, removing individual variation as a confound.

A 2025 randomized blinded cohort study found that combining PRP with microneedling produced superior periorbital rejuvenation compared to either treatment alone. This reflects a well-understood mechanism: controlled microtrauma opens dermal channels that improve distribution of the platelet concentrate, and the wound-healing response runs through the same growth factor pathways that PRP amplifies.

Platelet concentrate is a real but incremental tool for periorbital rejuvenation - one that works with the skin's biology over weeks and months, not one that produces immediate structural change.

A Newer Application: Injectable PRF for the Hollow Upper Eyelid

Most patient-facing content on platelet therapy focuses exclusively on the lower orbit. The superior sulcus - the groove between the upper lid and the brow - is an underappreciated target that recent evidence now supports.

Why the Superior Sulcus Hollows

With age, orbital fat atrophies, upper lid retractor tendons thin, and soft tissue volume diminishes throughout the brow and temporal zones. The deepened sulcus makes the eye look sunken or older than the patient feels. Conventional management has relied on hyaluronic acid filler, which restores volume but carries risks specific to this zone: named vessels in close proximity to the superior orbit mean that misplaced filler can cause vascular occlusion or pressure on adjacent structures.

The Arslan 2026 Case Series

A 2026 case series by Arslan and colleagues in the Journal of Cosmetic Dermatology applied injectable PRF to the superior sulcus in 12 patients. Mean sulcus depth at baseline measured 13.3 ± 2.8 mm. At three months, mean depth had fallen to 9.2 ± 3.7 mm (p = 0.002), with 75 percent of treated eyes rated as favorable outcomes. The mechanism is primarily biostimulatory: PRF drives native collagen and matrix production in tissue that has thinned, rather than displacing that tissue with foreign material. The volumetric effect is more modest than filler, but the safety profile in this anatomically sensitive zone is attractive. These are early-phase data from a small series; larger controlled trials are needed before the approach can be considered standard of care.

The Hard Limits: What Platelet Therapy Cannot Do and What That Means for Treatment Planning

The four-cause framework for dark circles discussed in the site article "Dark Circles Under the Eyes: The Four Causes" - vascular, pigmentation, shadow from volume loss, and structural laxity - maps directly onto treatment selection. PRP and PRF act on the vascular and pigmentation subtypes. The hollow and structural subtypes require different tools entirely.

• Herniated orbital fat - the structural cause of under-eye bags involves fat pushing forward through a weakened orbital septum. No growth factor combination tightens or repositions that structure. Lower blepharoplasty, with or without fat repositioning, is the appropriate intervention.
• Deep structural hollowing - moderate to severe tear trough deficit requires hyaluronic acid filler placed along the orbital rim, or autologous fat grafting in the right candidate. Platelet therapy cannot generate volume at that scale.
• Redundant or lax skin - loose lower lid skin that creates folds or shadowing requires either surgical excision or CO2 laser resurfacing. Collagen induction from PRP or PRF improves mild surface crepiness but will not tighten significantly lax tissue.
• Significant melanin deposits - periorbital hyperpigmentation driven by genetics or chronic inflammation often requires combination with topical depigmenting agents, chemical peels, or laser therapy for meaningful improvement.

The practical decision rule: when the primary finding is vascular-type darkness or surface texture change with intact tissue architecture, platelet therapy is a reasonable first-line option. When examination reveals herniated fat, significant hollow volume loss, or substantive skin laxity, the consultation should move toward the procedural or surgical options that address the actual anatomical problem.

Combining PRP and PRF with Other Periorbital Treatments

Platelet concentrate works well as part of a layered approach. Several combinations are supported by evidence or established clinical practice.

With microneedling: As the 2025 cohort study confirmed, combining PRP with microneedling outperforms either alone. Microneedling creates dermal channels that distribute the concentrate more evenly, and the wound-healing cascade it triggers runs through the same growth factor pathways that platelet therapy amplifies. Sessions are typically timed so both occur together or in close sequence.

With CO2 laser resurfacing: Fractionated or fully ablative CO2 laser handles surface irregularity, epidermal pigment, and superficial rhytids more aggressively than platelet therapy alone. PRP or PRF applied immediately after laser resurfacing accelerates healing and reduces post-procedural erythema duration - a practical advantage in periorbital work where recovery can be prolonged.

After blepharoplasty: Some oculoplastic surgeons incorporate PRF into the surgical field during blepharoplasty to support tissue healing. Separately, a course of injections several months post-operatively can address residual skin quality concerns once the surgical result has stabilized.

What not to combine: Hyaluronic acid filler and PRP or PRF should not be placed at the same session in the same tissue plane - hyaluronidase from activated platelets may partially degrade newly placed filler. Platelet therapy is also contraindicated at sites with active infection, inflammation, or recent herpes simplex outbreak.

The Treatment Experience: From Blood Draw to Maintenance

Understanding the session sequence and result timeline removes the main sources of uncertainty before a patient commits.

1. Topical anesthetic cream is applied to the periorbital skin and left in place for 20-30 minutes.
2. Blood is drawn from a peripheral vein and transferred to centrifuge tubes.
3. Centrifugation runs while the patient rests - two spins for PRP, one slower spin for PRF. PRF preparation takes only minutes and must proceed to injection without delay.
4. The concentrate is loaded into syringes with fine-gauge needles (26-32 gauge) and injected intradermally or immediately subdermally around the orbital rim. Volumes per side stay under 1 mL to respect the dense vascular anatomy of this region.
5. Gentle pressure is applied, the patient is observed briefly, then discharged with post-care instructions.

The full session takes 30 to 45 minutes. Because the product is the patient's own blood, there is no foreign material and no allergy risk - though bruising and swelling are still possible in this vascular territory. Both typically resolve within 24 to 72 hours.

Visible improvements in texture, color, and surface quality develop over 8 to 12 weeks after each session; platelet therapy is not a treatment where results appear at two weeks. Most protocols call for 2 to 3 sessions spaced 4 to 6 weeks apart to build a meaningful effect. A completed series holds for roughly 6 to 12 months, and maintenance injections on approximately that same interval sustain the result. Patients who prefer a permanent or longer-lasting outcome should be counseled toward the surgical options that provide one.

Frequently Asked Questions

Is PRP or PRF better for dark circles under the eyes?

It depends on the cause. For vascular-type darkness - a bluish or purple tint from vessels visible through thin skin - both products improve perfusion and increase dermal thickness, though PRP carries stronger published evidence for the pigmentation subtype specifically. For surface texture, fine lines, and crepiness, PRF's sustained release and higher platelet concentration make it the preferred choice in most periorbital protocols today. An examination that identifies the type of darkness present should guide the selection.

How many sessions are needed and how long do results last?

Most protocols call for 2 to 3 sessions spaced 4 to 6 weeks apart. Improvements develop gradually over 8 to 12 weeks after each session - not at two weeks. Results from a completed series hold for roughly 6 to 12 months, after which maintenance injections on a similar interval sustain what the initial series established.

Can platelet therapy fix bags under the eyes?

No. Under-eye bags are caused by herniated orbital fat pushing through a weakened orbital septum - a structural problem that growth factors cannot correct. Lower blepharoplasty, which repositions or removes that fat, is the appropriate procedure. PRP and PRF can improve skin quality in the area but will not change the underlying fat herniation.

Who is not a candidate for PRP or PRF around the eyes?

Absolute contraindications include platelet function disorders, coagulopathies, active use of anticoagulant medications, active infection or inflammation at the injection site, pregnancy, and autoimmune conditions affecting blood or connective tissue. Patients whose primary finding is herniated fat, significant volume hollowing, or substantive skin laxity are better served by procedures designed for those anatomical problems.

What is the superior sulcus, and can PRF treat it?

The superior sulcus is the groove between the upper eyelid and the brow that deepens with age as orbital fat thins and brow tissue descends. A 2026 case series found that injectable PRF reduced measured sulcus depth at three months, with 75 percent of treated eyes rated as favorable outcomes. The effect is biostimulatory rather than immediately volumetric, making PRF a consideration for early to moderate hollowing; deeper defects typically require filler or fat grafting to restore visible volume.

Is it safe to inject PRP or PRF around the eye?

In the hands of an injector with specific training in periorbital anatomy, the safety profile compares favorably to filler - there is no foreign material and no risk of vascular occlusion from volume displacement. The periocular region does have a rich vascular network, so technique matters: fine-gauge needles, small volumes, and precise tissue plane placement reduce bruising and vascular risk. Selecting a provider trained in periorbital injection - such as an oculoplastic surgeon who also performs surgical care in this zone - carries particular weight given how little margin for error the anatomy allows.